Interferons in the treatment of myeloproliferative neoplasms
Ther Adv Hematol. 2024 Feb 19;15:20406207241229588. doi: 10.1177/20406207241229588. eCollection 2024.ABSTRACTInterferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years. The initial use of interferons was limited due to difficulties with administration and a significant toxicity profile. Many of these shortcomings were addressed by covalently binding polyethylene glycol to the interferon structure, which increases the stability, prolongs activity, and reduces immunogenicity of the molecule. In the current th...
Source: Adv Data - February 21, 2024 Category: Epidemiology Authors: Pankit Vachhani John Mascarenhas Prithviraj Bose Gabriela Hobbs Abdulraheem Yacoub Jeanne M Palmer Aaron T Gerds Lucia Masarova Andrew T Kuykendall Raajit K Rampal Ruben Mesa Srdan Verstovsek Source Type: research
Interferons in the treatment of myeloproliferative neoplasms
Ther Adv Hematol. 2024 Feb 19;15:20406207241229588. doi: 10.1177/20406207241229588. eCollection 2024.ABSTRACTInterferons are cytokines with immunomodulatory properties and disease-modifying effects that have been used to treat myeloproliferative neoplasms (MPNs) for more than 35 years. The initial use of interferons was limited due to difficulties with administration and a significant toxicity profile. Many of these shortcomings were addressed by covalently binding polyethylene glycol to the interferon structure, which increases the stability, prolongs activity, and reduces immunogenicity of the molecule. In the current th...
Source: Adv Data - February 21, 2024 Category: Epidemiology Authors: Pankit Vachhani John Mascarenhas Prithviraj Bose Gabriela Hobbs Abdulraheem Yacoub Jeanne M Palmer Aaron T Gerds Lucia Masarova Andrew T Kuykendall Raajit K Rampal Ruben Mesa Srdan Verstovsek Source Type: research
Efficacy of Pegylated Interferon Alpha-2a in Uveitic Macular Edema Refractory to Biologic Agents
CONCLUSION: Pegylated interferon-alpha-2a can be used as an effective alternative to interferon alpha-2a in uveitic macular edema cases, resistant to other immunosuppressive agents.PMID:37917790 | DOI:10.1080/09273948.2023.2271980 (Source: Ocular Immunology and Inflammation)
Source: Ocular Immunology and Inflammation - November 2, 2023 Category: Allergy & Immunology Authors: Mohammad Avarand Mine Esen Baris Leila Taheri Suzan Guven Y ılmaz Source Type: research
A rare CALR variant mutation and efficient peginterferon alfa-2a response in a patient with essential thrombocythemia
Calreticulin (CALR) is a calcium-binding protein chaperone that may be found throughout the extracellular matrix and membranes of cells. It regulates calcium homeostasis and ensures the appropriate folding of newly generated glycoproteins within the endoplasmic reticulum. A somatic mutation in JAK2, CALR, or MPL is responsible for the great majority of essential thrombocythemia (ET) cases. ET has a diagnostic and prognostic value because of the sort of mutation that causes it. ET patients with the JAK2 V617F mutation had more noticeable leukocytosis, higher hemoglobin levels, and lower platelet levels, but also more thromb...
Source: Cancer Genetics and Cytogenetics - March 20, 2023 Category: Genetics & Stem Cells Authors: Rafiye Ciftciler, Ozgur Balasar Source Type: research
Direct Assessment of Oligomerization of Chemically Modified Peptides and Proteins in Formulations using DLS and DOSY-NMR
ConclusionThe correlation models of log(D) vs. log(MWhd) could be a quick and efficient way to predict MWhd of protein, which directly informs on the state of protein folding and oligomerization in formulation. (Source: Pharmaceutical Research)
Source: Pharmaceutical Research - January 10, 2023 Category: Drugs & Pharmacology Source Type: research
GSE207302 A genome-wide association study identified the variations nearby TP53BP2 promote HBsAg loss in patients treated with peginterferon alfa-2a through enhancing interferon response of hepatocytes [HepG2]
In this study, we found for the first time that the rs7519753 located at 1q41 was associated with HBsAg loss in CHB patients after interferon treatment. Further functional analysis confirmed that the rs7519753-C genotype was associated with the high expression of TP53BP2 in the liver. In addition, TP53BP2 enhanced the activation of interferon pathway by inhibiting the expression of SOCS1 and SOCS2, thereby enhancing the anti-HBV effect of interferon. The outcome of this study may help us to identify CHB patients who will achieve HBsAg loss before the start of pegylated IFN- α-based therapy and reach functional cure. (Sour...
Source: GEO: Gene Expression Omnibus - January 1, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
GSE207303 A genome-wide association study identified the variations nearby TP53BP2 promote HBsAg loss in patients treated with peginterferon alfa-2a through enhancing interferon response of hepatocytes
Series Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - January 1, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
GSE207301 A genome-wide association study identified the variations nearby TP53BP2 promote HBsAg loss in patients treated with peginterferon alfa-2a through enhancing interferon response of hepatocytes [HepAD38]
In this study, we found for the first time that the rs7519753 located at 1q41 was associated with HBsAg loss in CHB patients after interferon treatment. Further functional analysis confirmed that the rs7519753-C genotype was associated with the high expression of TP53BP2 in the liver. In addition, TP53BP2 enhanced the activation of interferon pathway by inhibiting the expression of SOCS1 and SOCS2, thereby enhancing the anti-HBV effect of interferon. The outcome of this study may help us to identify CHB patients who will achieve HBsAg loss before the start of pegylated IFN- α-based therapy and reach functional cure. (Sour...
Source: GEO: Gene Expression Omnibus - January 1, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Cancers, Vol. 14, Pages 5495: Recombinant Interferon- & beta; in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
Cancers, Vol. 14, Pages 5495: Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives
Cancers doi: 10.3390/cancers14225495
Authors:
Hans Hasselbalch
Vibe Skov
Lasse Kjær
Morten Kranker Larsen
Trine A. Knudsen
Marko Lucijanić
Rajko Kusec
About 30 years ago, the first clinical trials of the safety and efficacy of recombinant interferon-α2 (rIFN-α2) were performed. Since then, several single-arm studies have shown rIFN-α2 to be a highly potent anticancer agent against several cancer types. Unfortu...
Source: Cancers - November 9, 2022 Category: Cancer & Oncology Authors: Hans Hasselbalch Vibe Skov Lasse Kj ær Morten Kranker Larsen Trine A. Knudsen Marko Lucijani ć Rajko Kusec Tags: Perspective Source Type: research
MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
Context: Low-dose aspirin with hydroxyurea (HU) is first-line therapy in high-risk essential thrombocythemia (ET). However, many patients become HU-intolerant or -resistant. Anagrelide (ANA) and peginterferon alfa-2a are second-line options for high-risk ET patients. Objective: To assess the long-term safety and efficacy of P1101 compared to ANA as a second-line option for ET patients with HU intolerance or resistance Design: Phase 3, open-label, multicenter, randomized, active-controlled study to assess the efficacy, safety, tolerability after 12 months of treatment with a 28-day screening and follow-up, for a total trial...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 21, 2022 Category: Hematology Authors: Ruben Mesa, Norio Komatsu, Harinder Gill, Jie Jin, Sung-Eun Lee, Hsin-An Hou, Toshiaki Sato, Albert Qin, Raymond Urbanski, Weichung Shih, Oleh Zagrijtschuk, Craig Zimmerman, Srdan Verstovsek Tags: Myeloproliferative Neoplasms Source Type: research
Changes in serum hepatitis B surface and e antigen, IP-10, and aminotransferase levels during combination therapy of immune tolerant chronic hepatitis B
CONCLUSIONS: Induction of IP-10 during peginterferon treatment in adults and children in the IT phase of chronic HBV infection is associated with ALT elevations and decline in viral antigens suggesting a degree of interferon-inducible viral control.PMID:35188674 | DOI:10.1002/hep.32400 (Source: Cancer Control)
Source: Cancer Control - February 21, 2022 Category: Cancer & Oncology Authors: Robert P Perrillo Hsing-Hua S Lin Kathleen B Schwarz Philip Rosenthal Mauricio Lisker-Melman Raymond T Chung Ludmila Prokunina-Olsson Gavin Coherty Jordan Feld Hepatitis B Research Network (HBRN) Source Type: research
Treating Childhood Social Anxiety Disorder With Virtual Environments and Serious Games: A Randomized Trial
Behav Ther. 2021 Nov;52(6):1351-1363. doi: 10.1016/j.beth.2021.03.003. Epub 2021 Mar 18.ABSTRACTDisseminating efficacious psychological treatments remains a challenge for researchers and clinicians. In the case of social anxiety disorder (SAD), Social Effectiveness Therapy for Children (SET-C) has been demonstrated as an efficacious intervention, but elements of the protocol, such as peer generalization sessions, remain challenging to conduct in typical clinical settings. To address this need, we developed an artificially intelligent, web-based application, Pegasys-VR™, designed to replace peer generalization sessions an...
Source: Behavior Therapy - October 17, 2021 Category: Psychiatry & Psychology Authors: Deborah C Beidel Peter W Tuerk Josh Spitalnick Clint A Bowers Krystal Morrison Source Type: research
Treating Childhood Social Anxiety Disorder With Virtual Environments and Serious Games: A Randomized Trial
Behav Ther. 2021 Nov;52(6):1351-1363. doi: 10.1016/j.beth.2021.03.003. Epub 2021 Mar 18.ABSTRACTDisseminating efficacious psychological treatments remains a challenge for researchers and clinicians. In the case of social anxiety disorder (SAD), Social Effectiveness Therapy for Children (SET-C) has been demonstrated as an efficacious intervention, but elements of the protocol, such as peer generalization sessions, remain challenging to conduct in typical clinical settings. To address this need, we developed an artificially intelligent, web-based application, Pegasys-VR™, designed to replace peer generalization sessions an...
Source: Behavior Therapy - October 17, 2021 Category: Psychiatry & Psychology Authors: Deborah C Beidel Peter W Tuerk Josh Spitalnick Clint A Bowers Krystal Morrison Source Type: research
